Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effective Degradation of Wild-Type and Mutant EGFR Using Self-Assembling Peptide-Derived PROTAC Nanoparticles (NanoTACs) for Cancer Therapy.

Advanced materials (Deerfield Beach, Fla.) - 1 Feb 2026

Jeong Joohee, Cho Hanhee, Moon Yujeong, Shim Nayeon, Kim Jeongrae, Kim Jinseong, Choi Sungchan, Park Jung Yeon, Kim Yongju, Kim Kwangmeyung

Abstract excerpt

Epidermal growth factor receptor (EGFR)-targeted therapeutics, including monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs), have achieved clinical success but are limited by drug resistance and off-target toxicity. Herein, self-assembling peptide-derived PROTAC nanoparticles (NanoTACs) engineered for effective degradation of both wild-type and mutant EGFR for cancer therapy is reported. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Nanoparticles

Share to Neoplasms

Share to Peptides

Share to Protein Kinase Inhibitors

Share to Proteolysis

Source

Identifiers

PMID: 41386736
DOI: 10.1002/adma.202516974

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effective Degradation of Wild-Type and Mutant EGFR Using Self-Assembling Peptide-Derived PROTAC Nanoparticles (NanoTACs) for Cancer Therapy.PMID 41386736Read ↗

Design, synthesis, and biological evaluation of novel probe-quality EGFR degraders targeting wild-type and Del19 mutation.Semantic proximity Read ↗

Hybrid nanovesicles enhance antitumor efficacy in KRAS-mutant non-small cell lung cancer.Semantic proximity Read ↗

A Recombinant Targeted Bionanoparticle In Vitro Expressing a Gene-Editing Protein for Epidermal Growth Factor Receptor Mutant Lung Cancer.Semantic proximity Read ↗

Targeted Protein Degradation via NanoparticlesSemantic proximity Read ↗

Cancer Selective Target Degradation by Folate-Caged PROTACsSemantic proximity Read ↗

Ligand conjugated lipid-based nanocarriers for cancer theranosticsSemantic proximity Read ↗

Next generation protein-corrole bio-assemblies provide effective tumoricidal treatment in a metastatic triple-negative breast cancer modelSemantic proximity Read ↗

Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands.Semantic proximity Read ↗

Multiparatopic antibodies overcome tyrosine kinase inhibitor resistance by inducing lysosomal degradation of EGFR mutants.Semantic proximity Read ↗

Next generation protein-corrole bio-assemblies provide effective tumoricidal treatment in a metastatic triple-negative breast cancer modelSemantic proximity Read ↗

Multiparatopic antibodies overcome tyrosine kinase inhibitor resistance by inducing lysosomal degradation of EGFR mutantsSemantic proximity Read ↗

Extreme Hydrophobicity of Cytotoxic Drugs Enables Design of Next Generation Antibody-Drug Conjugates NanotherapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.